- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Verastem Inc.
Headquarters: Needham, MA, United States of America
Website: http://www.verastem.com
Year Founded: 2010
Status: Public
Industry Sector: HealthTechnology
CEO: Dan Paterson
Number Of Employees: 78
Enterprise Value: $138,072,210
PE Ratio: -2.15
Exchange/Ticker 1: NASDAQ:VSTM
Exchange/Ticker 2: N/A
Latest Market Cap: $386,174,976
BioCentury | Apr 25, 2025
Finance
Pair of European start-ups launch with innovative antibodies: Finance Report
Plus: Flagship unveils disease interception play Etiome; Verastem raises $75M PIPE; and more
BioCentury | Jan 22, 2025
Management Tracks
Fabrice Chouraqui to become CEO of Pharming
Plus: Woodcock, Kim join Friends of Cancer Research’s board and updates from Recursion, Medtronic and more
BioCentury | Jan 18, 2025
Management Tracks
Moves at FDA, NIH
Plus: updates on AZ, Actimed, Kailera, Nasus and more
BioCentury | Jul 26, 2024
Finance
Public Equity Report: Palvella lands on NASDAQ via Pieris merger
Plus: Verastem’s follow-on and Hangzhou Jiuyuan’s IPO plans
BioCentury | Apr 19, 2024
Management Tracks
Domain, Initial among quartet of biotechs unveiling CEOs
Plus: Jim Jenson becomes CEO of Morphoceuticals, and updates from Xeno, NeoGenomics, DeepUll and Verastem
BioCentury | Oct 27, 2023
Management Tracks
CFO John Kuch to retire from Xencor
Plus: Verastem hires new commercial and regulatory heads, and new CTO at Actym
BioCentury | Aug 28, 2023
Politics, Policy & Law
Aug. 28 Quick Takes: Horizon shares rise as FTC suspends challenge to Amgen deal
Plus: RA leads $33M seed in Superluminal and updates from Bayer’s BlueRock, Novocure, Verastem-GenFleet, Danaher-Abcam
BioCentury | Jul 12, 2023
Management Tracks
Eisai’s Cheung, head of U.S. and Leqembi lead, retiring
Plus: Paterson becomes CEO of Verastem, and updates from
BioCentury | Jan 26, 2023
Product Development
Jan. 25 Quick Takes: Merck reports mixed Phase III Keytruda results
Plus: updates from Verastem, Vertex-CRISPR and Genentech
BioCentury | Sep 3, 2022
Data Byte
September’s FDA advisory committee line-up
Three cancer therapies on the agenda, plus an ALS therapy and a live fecal microbiota
Items per page:
1 - 10 of 149